Method of producing derivatives of 1,4-dihydropyridine

专利摘要:
Novel dihydropyridine derivatives which are useful for treating congestive heart failure, hypertension, and angina have the formula 1: <IMAGE> (1) or a pharmaceutically acceptable acid addition salt thereof, wherein: n is an integer from 0 to 8; Y is -O, -NH, -NR2, -S, -S(O), -S(O)2, or a bond; R1 and R2 are each independently A1, A2, A3 or A4 where: A1 is -(CH2)m(CHOH)pCH2OH; A2 is -(CH2)qCH(3-r)[(CH2)sOH]r; A3 is -(CH2)qCH(3-r)[(CH2)pCOOR3]r; and A4 is -(CH2)mCOOR3; where: m is an integer from 1 to 8; p is an integer from 0 to 4; q is an integer from 0 to 8; r is 2 or 3; s is an integer from 1 to 4; and R3 is H or alkyl of 1 to 18 carbon atoms; R4 is -NO2, -CF3, or halo; and R5 is lower alkyl or -CH2CH2OCH3.
公开号:SU1598870A3
申请号:SU864023644
申请日:1986-02-10
公开日:1990-10-07
发明作者:Дуглас Кларк Робин；Майкл Повжитков Моисей
申请人:Синтекс (Ю.С.А.) Инк (Фирма)；
IPC主号:

专利说明:

3-NO-i-C6H4-CH-C C (.0) (CH3) -NH-CCCH3 C-C (ObO- (CH iV-C6H.,
where Y is - or -NH-; 1C - group A or A,
those. A, - (SNON) p-CH, OP; Aj, -CH, -CH (CH, i-nH) 2 with p 0 or 1 or 2, shows a yurdim antihypertensive 3-N02-C6H4-CH-C C (0) (CH.iVNH-CCCH) CC (0 ) -0- (CHi H-C6H - -YR
Where
R; A, or A, i.e. A, (CH-OG) p-CH -OC and A ,, CHj-CH (,),.
where Oj and C (independently) - H or benzyl, but provided that one of them. H, or () - С (СНз) - or neighboring О, and 0 together form the group C (CH, j), j-. From the specified substance is removed with the correct group by treatment
The invention relates to the field of production of new heterosclic
This activity can be used in medicine. The goal is to create new, more active and less toxic substances of the specified class. Synthesis of lead from compound f-ly
) C-C (0) -0- (CHi H-C6H - -Y-R
I
diluted with HC1 in proton solvent in the case when P and P or neighboring P and O form a -C (CHj) - group, or dealkylation is performed under conditions of catalytic hydrogenation, when P and / or P mean a benzyl group. New substances have low toxicity and are active in doses of 1-7.0 mg / kg. 3 tab.
cl
with
00
00 Cj

O4
compounds, in particular the 1,4-dehydropyridine derivative of the general formula
(I)
CH300C-YV 2) 5
CH
Nh
SNS
where Y is the group -0-, -Nil-;
R is a group of formula A, or A, where A, - —CH ,, - (CHOH) p — CH, OH;
A - -CH ,, - CHfCH OlO5, where or 1; .
 or 2,
EXPLOSIVE antihypertensive activity that can be used in medicine.
The aim of the invention is to create, on the basis of known methods of crtoco, for the preparation of compounds exhibiting high antihypertensive activity with low toxicity ..;
Example 1. A solution of 21 g of 2,6-di methyl-3-methoxycarbonyl-4- (3-nitrophenyl) -5 - ((2, 2-dimethyl-1, 3-dioce, pan-4-yl ) methoxyphenyl Zethox icarbonylJ-1,4-dihydropyridine. In 150 ml of acetone and 50 ml of water are treated with 10 ml of hydrochloric acid, then the mixture is boiled for 6 hours. After adding 500 ml of water, the mixture is extracted with ether. The ether layer is dried over after evaporation of the solvent, the resulting oil is purified by moderate pressure chromatography on silica gel (90% ethyl acetate in hexane) to give 12 g of 2,6-dimethyl-3-methoxycarbonyl-4- (3-nitrophenyl) -5-2-G4- (2.3 -dihydroxypropoxy) phenyl ethoxycarbonyl} -1.4 dihydropyridine (I) as a thick oil that crystallizes when washed with ethyl acetate, mp 117-118 C.
Found,%: C 61.42; H 5.76; N 5.31.
C. ,,, oe. Calculated N5,32.
C, 61.59; H 5.74;
Example 2. Analogously to example 1, but using instead of 2,6-dimethyl-3-methoxycarbonyl-4- (3-nitrophenyl) (2,2-dimethyl-1,3-dioxalan-4-yl) methoxyphenyl } ethoxycarbonyl -1,4-dihydropyridine corresponding starting compounds, the following compounds are obtained:
1 - 2,6-d1-1methyl-3-methoxycarbonyl-4- (3-nitrophenyl) (3,4-dihydroxy propoxy) phenyl methoxy.carbonyl-1.45
0
five

0
5 do
thirty
35
45
Jq.
dihydropyridine, IR: 3600-3100, 1680, 1249
2- 2,6-dimethyl-3-methoxycarbonyl-4- (3-nitrophenyl) -4 - ((2,3-dihydroxypropoxy) phenyl propoxycarbonyl} - 1,4-dihydropyridine, mp 121-124 WITH;
3- 2,6-dimesh1-3-methoxycarbonyl-4- (3-nitrophenyl) -5-C4- (1,3-dihydroxy-propoxy) phenyl methoxycarbon-1-1.4-dihydropyridine, m.p. 58-60 ° C;
4- 2,6-dimethyl-3-ztoxycarbonyl-4- (3-nitrophenyl) -5- {2-4- (1,3-dihydro-xyproproxy) phenylJ ethoxycarbonyl J-1,4-dihydropyridine, T..PL . 56-58 C;
5- 2,6-dimethyl-3-methoxycarbonyl-4- (3-nitrophenyl) -5-2 - {: 4- (2-hydroxymethyl-3-hydroxypropoxy) phenylLethoxyka.rbonyl} -1,4- dihydropyridine, SHR (CDClj): 2.3 (singlet, 3N), 2.34 (singlet, 3N), 2.85 (multiplet, 2H), 2.65 (singlet, 3N), 3.92 (doublet, 4H ) 4.1 (doublet, 2H), 4.25 (triplet, -2H),
5.04 (singlet, 1H), 6.8 (doublet, 2H),
7.05 (doublet, 2H), 7.35 (triplet, 1H), 7.5 (double triplet, 1FI), 7.95-8.05 (multiplet, 2H);
6- (a +) - 2,6-dimethyl-3-methoxycarbon-1-4- (3-nitrophenyl) -5- {2-C4- (2.3 dihydroxypropoxy) phenyl ethoxycarbonyl} -1,4-dihydropyridine ( 1-, 0., -33.5);
7- (a -) - 2,6-dimesh1-3-methoxycarbonyl-4- (3-nitrophenyl) -5- {2- 4- (2., 3-dihydroxypropoxy) phenyl ethoxycarbons J.1, 4-dihydropyridine (1 a-, o-28);
8- (b +) - 2,6-dimethyl-3-methoxy-carbonyl-4- (3-nitrophenyl) (2,3-dihydroxy-propoxy) phenyl-ethoxy-carboxyl 5 -1,4-dihydropyridine (lb +, c /., 2);
9- (b -) - 2,6-dimethyl-3-methoxycarbonyl-4- (3-nitrophenyl) -5- {2- 4- (2,3-dihydroxypropoxy) phenyl-toxycarbonyl-1-1,4- dihydropyridine (1b-, / +34 ").
Example In compounds of formula (II) protected as benzyl ethers, the protecting group is removed as follows.
A solution of 6.2 g of 2,6-dimethyl-3-methog xycarbonyl-4- (3-nitrophenyl) (2-benzsh10oxyethoxy) phenyl ethoxycarbonyl -1,4-dihydropyridine in 100 ml of ethanol is hydrogenated for 18 h under a pressure of 50 lb / inch (3, .5 ati) in the presence of 0.5 g of 10% palladium on carbon. The resulting mixture is filtered and after isp 1598870
filtrate vapors receive 2,6-dimethyl-3-methoxycarbonyl-4- (3-nitrophen. -nyl) -5-2-G4- (2-hydroxyethoxy) phenyl ethoxycarbon-1-1,4-dihydropyridine, t .pl. 133-135 C.
II p and me R 4. Analogously to example 3, but using instead of 2,6-dimethyl-3-methoxycarbonyl-4- (3-nitrophensh1) -5-2- / 4- (2-benzyloxyethoxy) - phenyl ethoxycarbonyl -1,4-dihydrpyridine corresponding to the starting materials of the starting compounds the following compounds are obtained
1 2,6-dimethyl-3-methoxycarbonyl10
Systolic blood pressure (i.e., pressure at the onset of the first pulse) is recorded with a photoelectric sensor. The coccyx arteries in 3 rats (from the group in the horizontal position) are simultaneously closed using tail cuffs, in which a pressure of 300 mm Hg is automatically created by the pump, which is then released. The pressure curve and tail pulse are simultaneously recorded using a chart recorder. Record four consecutive
4- (3-nitrophenyl) -5- 2-C4- (2-hydroxy-, 5 signals (with an interval of 30 s) for each amino-amino) fennp ethoxycarbonyl -1,4 up to rat through 1,2,3 and 4 hours after the introduction of dihydropyridine, so pl. 102-104 ° Cj
2 - 2,6-dimethyl-3-methoxycarbonyl-4- (3-nitrophenyl) (2-hydroxyethyl) aminophenylZethoxycarbonyl - 20 1,4-dihydropyridine, T.PL. 90-92 ° C.
Biological testing.
I. Experiments on spontaneously hypertonic rats. Twenty-four pre-trained adult male spontaneously hypertonic rats are divided into 6 groups (4 animals per group) with approximately the same mean systolytic blood pressure.
25
day connection. Similarly, tests were performed for each successive group in a horizontal position. Calculate mean systolic blood pressure (SCR) for each rat at each observed time value. Using a one-way analysis with a dispersed criterion, SC, C animals are compared in each dosage group with SCRs of animals in the control group (carrier only) in each observed time interval. Compounds showing p, 05 in
- ----... J itv / n.ci.joi0ciiuL t: р V and J В
After that, 6 groups are studied at the same time as the observed time interval.
Concomitant trials were counted by developing significant pro- ges. Each group was randomly assigned a hypertonic effect. Compounds that reduce blood pressure - - by 20 mm Hg or more from control ones receive potentially counterterm values in all four observables and one control time interval, considering the kg group receives only the carrier (water that deserves further study. The heartbeat is measured and tested for a significant 40 heartbeat changes compared with the control measurements, using the double-tail test method for this.
Lpg, ml7pk, t of t, 7 through 1,2,3 and 4 h after dosing on
 on "" - 45 and the second day. The proposed compounds tested in 80 g of UOM ° were in 80 using a homogenizer in such an anti-hypertonic active-.
test compounds. Five groups
and twin).
Approximately 17 hours before the first day of dosing, food was removed from the rat cells. On the morning of the first day, a group of 4 rats was orally administered (via a stomach tube) 12.5 or 25 mg / kg of the compound.
ness (see table. 1).
concentration, that O, 1 ml of solution is per 10 g of body weight. After 4.5 hours
after the introduction of the dosage, the food will return to 50 II. Echocardiography in the experiments on the ground into the cells and left for 2.5 hours, - - after which the food is removed again. On the morning of the second day, the rats were administered the dosage of the compound again in the manner described.
dogs. A group of mongrel dogs weighing 18–25 kg is selected to create clear images that can be obtained on them with the help of ultrasound PIL PIL. Li with the help of TRASONIC STR.
Immediately after administration of the dosage of the rat 55 echocardiography in two dimensions
ZyklyuYayuyut P tglgg and gt gt ".hch." / L ....
enclosed in retainers and placed in a heated chamber () for 4 hours. Normal feeding is resumed at the end of the experiment on the second day.
(2IE). From the selected group of dogs used in two ways with the use of 2IE. In the first case, the dogs are anesthetized; in the second case, they are
0
Systolic blood pressure (i.e., pressure at the onset of the first pulse) is recorded with a photoelectric sensor. The coccyx arteries in 3 rats (from the group in the horizontal position) are simultaneously closed using tail cuffs, in which a pressure of 300 mm Hg is automatically created by the pump, which is then released. The pressure curve and tail pulse are simultaneously recorded using a chart recorder. Record four consecutive
5 signals (with an interval of 30 s) for each rat after 1, 2, 3 and 4 hours after
, 5 signals (with an interval of 30 s) for each rat after 1, 2, 3 and 4 hours after
20
25
day connection. Similarly, tests were performed for each successive group in a horizontal position. Calculate mean systolic blood pressure (SCR) for each rat at each observed time value. Using a one-way analysis with a dispersed criterion, SC, C animals are compared in each dosage group with SCRs of animals in the control group (carrier only) in each observed time interval. Compounds showing p, 05 in
---... J itv / n.ci.joi0ciiuL t: р V and J В
Zolyub observable time span
 and second day ° proposed with antihypertensives
ness (see table. 1).
 Ii. Echocardiography in experiments on - -
dogs. A group of mongrel dogs weighing 18–25 kg is selected to create clear images that can be obtained on them using ultrasound — J I o pa PIL. Li HELP STR.
howl echocardiography in two dimensions
howl echocardiography in two dimensions
/ l ....
(2IE). From the selected group of dogs used in two ways with the use of 2IE. In the first case, the dogs are anesthetized; in the second case, they are
dts is conscious and not exposed to sedatives.
In both cases, a small branch of the femoral artery is inserted through a section through the artery into a cannula in the form of a water-filled tubule connected to a pressure transducer. In the case of conscious dogs, the incision of the femoral artery is anesthetized topically with a subcutaneous injection of lidocaine. Such a sensor makes it possible to register pressure. Blood pressure and ECG are recorded on a two-channel recorder.
In the fourth or fifth intercostal space in the right underbelly, an ultrasonic device is placed with a canister connected to a special
15988708
I
dosages of 5.2.1 and 0.75 mg / kg of the compound in gelatin capsules. Control values are obtained before each dosage. With intravenous injection of the scientific research institute, additional measurements were carried out at intervals of 5, 10, 15, 30, 45 and 60 minutes after the administration of each dosage. When administered orally, additional
Q measurements are obtained in the intervals of 10.20, 30, 45.6, 0.75, 90.10, 105, 120 and 180 minutes after the administration of each dosage. In the experiment, the proposed compounds showed positive activity.
J5 A. Experiments on anesthetized dogs. Outbred dogs weighing 14-21 kg are anaesthetized with penta-barbital sodium (35 mg / kg, intravenously), after which they are introduced into the cannula.
a 3 μHz transducer, creating 20, opens the chest in the left fifth intercostal space. The animals have sensors for measuring the following parameters: systolic, diastolic and average blood pressure, 25 heart rate, left ventricular pressure, dp / dt max values in the left ventricle, pulmonary capillary wedge pressure, central venous pressure, minute 30 volume heart, somatic vascular resistance, compressive strength and coronary blood flow.
2IE images. Such images include a view along the long axis of the left ventricle, indicated by the simultaneous imaged apex, the mitral valve and the circular left atrium, an image of the papillary muscular layer is obtained along the short axis. Further analysis of all images is recorded. on videotape. The analysis is carried out using a computerized graphics program associated with a video recorder and a repository of information.
In the first case, the dogs are anesthetized with sodium barbital. Putting them
on the right side of the machine, allowing access through the incision to the right underbelly. During the course of the day, doses of 50, 100, 200, and 500 mg / kg of the proposed compound were intravenously administered to the dogs. The compounds are dissolved in a mixture of distilled water and dimethylacetamide (2: 1). For each dosage, control values are obtained and measurements are taken at 3, 5, 10, 15 and 30 minutes after administration of each dosage.
In the second case, the dogs are trained to stand quietly for several hours in the machine. The right underbelly of these dogs is accessible through the control panel and the button panel. Intravenously administered dosages of 200 and 250 mg / kg of the proposed compound dissolved in a mixture of distilled water with ethanol (7: 1), as well as dosages of 150 and 100 mg / kg of a compound dissolved in a mixture of distilled water and dimethylacetamide (3 :one). In addition, orally administered
 open the chest in the left p
ABOUT

rib space. The animals have sensors for measuring the following parameters: systolic, diastolic and average blood pressure, 5 heart rate, left ventricular pressure, dp / dt max values in the left ventricle, pulmonary capillary wedge pressure, central venous pressure, minute 0 volume heart, somatic vascular resistance, compressive strength and coronary blood flow.
The pressure in the left ventricle is measured using a Millar catheter with a microtip. The electronic unbalance of this signal gives dp / dt ha. Systolic, diastolic, averaged blood pressure and central venous pressure are obtained using a Statesham pressure-filled pressure sensor. The minute volume of the heart and pulmonary capillary wedge pressure are measured using a Swan-Ganz catheter connected to a 45 USSHEM pressure sensor, filled with fluid, and a digital computer. Compressive strength is measured using Walton-Brody monometrical arc, hanging in the left ventricle. Somatic vascular resistance is calculated based on measurements of the heart’s minute volume and blood pressure. Epicardial blood flow is measured using an electromagnetic flow sensor (manufactured by Carolina Medical Electronics). The myocardial blood stream is measured using a microsphere, p with 5 labeled atoms: (5Sr, Sn, Cr, and Sc).
50
55
The data is processed using a Packard 3500 gamma counter model and a Canberra model multi-channel microanalyzer and analyzed using a computer.
The proposed compound is prepared for administration in dimethylacetamide (as carrier) or saline for intravenous injection, or in dimethylacetamide and water for intraduodenal use. Corresponding control measurements are made.
One group of animals was intravenously injected with the proposed compound in the following dosages: 25,50,10,200 and 500 mg / kg. These parameters are measured at least 30 minutes after each dosage.
Another group of animals is provided with a compound to be administered into a vein to detect the direct local effect of the compound. All of the above ... parameters are measured 10-15 minutes after drug administration (with the exception of the radioactive method for measuring myocardial blood flow). Dosages applied are 1, 2, 5, 10 and 20 mg / kg.
The obtained data are summarized at averaged values of the standard deviation from the average value. Where indicated, statistical processing was performed on the basis of paired and non-paired t-analysis of Student. -.
In tab. 1 - 3 shows the results of experiments.
As can be seen from the above, the proposed compounds are active.

权利要求:
Claims (1)
[1]
Formula
The method of obtaining 1,4-dihydropyridine derivatives of the general formula
CHjOOC
NiD2 (I)
coo- (cH2)
SNS
Q
0
50
,
0
If
five
: where Y is the group -0-, -NH-;
R., is a group of formula A or A, where A is ((CHOH-))
AiCH2-CH (SNGON) 2,
where p O or 1; n 1 or 2
characterized in that in the compound of the general formula
south
CH30XyCcOO- (CH2) n42) -YRi CH3 N CH.
n
where Y is the group -0-, -NH-;
R {is a group of formula A, or A where A, - (CHOG,) is ClIiOG2; .. A - -CH.j-CH (CH, OG);
p has the indicated meanings; G and, independently of each other, hydrogen or benzyl, provided that one of them is necessarily different from hydrogen, or 0 and G .J together form a group of the formula C (CH), w: .and the adjacent Gj and 0 together form a group of the formula С (СНз), g,
the protective group is removed by treatment with dilute hydrochloric acid in a proton solvent, in the case when G and G or neighboring G, and G forms the .C (CHj) group, or in the case when G and / or G is a benzyl group, des - by alkylation under conditions of catalytic hydrogenation.
About V-0
RsO D JI O-fcH ln-NzS
n
About you
5o; is - n- @
NZS
ten
25
50
100
200
500
ten
25
TRi
table 2
Yri
t a b l and c a 3
2070 2205 1830 1860 1995 2565 2565 2580
13
The minute volume of the heart, the degree of compressibility or pressure change in the left
ventricle.
The compound was tested in the range of 5–20 mg / kg, administered to dogs intraduodenally, no toxic. no significant effect. All dosages are intravenous.
Compiled by N. Bannikova Editor S, Baker Tehred L. Oliynyk Proofreader N. Revska
Order 3076
Circulation 322
VNShPI State Committee for Inventions and Discoveries at the State Committee on Science and Technology of the USSR 113035, Moscow, Zh-35, 4/5 Raushsk nab.
.i - “., --.- ...-.„, ------- - - - - ..- в ™. ... ". ..and"--.-. - ..- ..
Production and publishing plant Patent, Uzhgorod, st. Gagarin, 101
1598870
14 Continuation of the table. Subscription

类似技术:

---

公开号 | 公开日 | 专利标题

---

SU1248533A3|1986-07-30|Method of producing sulfamoyl-substituted derivatives of phenethylamine or hydrochloride thereof

---

Perkins et al.1950|Renal and cardiac lesions in potassium deficiency due to chronic diarrhea

---

Patel1984|Terfenadine in exercise induced asthma.

---

US3466325A|1969-09-09|1-| - 2-hydroxy-3-isopropylaminopropanes and the salts thereof

---

Anrep et al.1946|Ammi visnaga in the treatment of the anginal syndrome

---

US4470965A|1984-09-11|Celiprolol for the treatment of glaucoma

---

RU2270679C2|2006-02-27|Medicinal agent for hypertension treatment

---

EP1163224B1|2003-04-16|N-[2-hydroxy-3-|propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance

---

SU1598870A3|1990-10-07|Method of producing derivatives of 1,4-dihydropyridine

---

EP0038343A1|1981-10-28|Substituted carboxylic ceto-acids, process for the preparation thereof, use thereof and medicinal compositions containing them.

---

CN1477957A|2004-02-25|Tanshinone compound containing dihydrofuran ring structure for curing hyperammonemia and hepatic encephalopathy

---

US4010274A|1977-03-01|Isoindoline derivatives having platelet anti-aggregating activity

---

CN101230035B|2010-11-03|Aspartic acid amlodipine series salt as well as preparation method, composition, preparation and tablets thereof

---

US5789439A|1998-08-04|Pharmaceutical use of forskolin derivatives

---

WO1994005290A1|1994-03-17|Platelet aggregation inhibitor

---

CN108715579B|2020-03-24|Organic amine ester derivative medicine of 2- | benzoic acid

---

US4418070A|1983-11-29|Cardiotonic agents

---

RU2295968C2|2007-03-27|Combined preparation possessing sedative, spasmolytic and anti-allergic effect

---

US4562206A|1985-12-31|Orally effective inotropic compounds

---

WO1995005825A1|1995-03-02|Circulatory disturbance ameliorant

---

DE2924880A1|1980-01-24|2-AMINOOCTAHYDROINDOLO SQUARE CLAMP ON 2.3-A SQUARE CLAMP FOR CHINOLIZIN COMPOUNDS, METHOD FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THEM

---

US5441962A|1995-08-15|Method for treating hyperlipemia

---

DE2034640B2|1979-09-27|

---

US4061756A|1977-12-06|Methods for treating cardiovascular disorders

---

US4855497A|1989-08-08|Novel diamine derivatives

同族专利:

---

公开号 | 公开日

---

DD242804A5|1987-02-11|

---

ZA86966B|1987-10-28|

---

US4595690A|1986-06-17|

---

DD252601A5|1987-12-23|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US4031104A|1972-04-18|1977-06-21|Bayer Aktiengesellschaft|1,4-Dihydropyridine carboxylic acid esters|

---

US3985758A|1973-02-20|1976-10-12|Yamanouchi Pharmaceutical Co., Ltd.|1,4-Dihydropyridine derivatives|

---

DE2508181C2|1975-02-26|1988-12-01|Bayer Ag, 5090 Leverkusen, De|

---

US4154839A|1975-11-05|1979-05-15|Bayer Aktiengesellschaft|2,6-Dimethyl-3-carboxymethoxy-4--5-carbisobutoxy-1,4-dihydropyridine|

---

DE2639498A1|1976-09-02|1978-03-09|Bayer Ag|NEW SULFUR-CONTAINING AMINO-DIHYDROPYRIDINES, THE PROCESS FOR THEIR MANUFACTURING AND THEIR USE AS A MEDICINAL PRODUCT|IL77843A|1985-02-11|1989-07-31|Syntex Inc|Dihydropyridine derivatives,process and novel intermediates for their preparation and pharmaceutical compositions containing them|

---

US4761420A|1986-06-13|1988-08-02|Laboratoires Syntex S.A.|Antihypertensive dihydropyridine derivatives|

---

US4886819A|1986-08-27|1989-12-12|The Green Cross Corporation|Dihydropyridine derivatives and pharmaceutical composition thereof|

---

US4920225A|1986-12-22|1990-04-24|Laboratoires Syntex S.A.|Resolution of 1,4-dihydropyridine derivatives|

---

ES2119748T3|1990-03-23|1998-10-16|Yoshitomi Pharmaceutical|PHARMACEUTICAL COMPOSITION CONTAINING A PHARMACEUTICALLY SOLUBLE IN WATER.|

---

US5100892A|1990-11-13|1992-03-31|Glaxo Inc.|Dihydropyridine vasodilator agents|

---

US7488748B2|2003-01-28|2009-02-10|Ranbaxy Laboratories Limited|3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

US06/700,439|US4595690A|1985-02-11|1985-02-11|Antihypertensive dihydropyridine derivatives|

---